An international team led by Professor Samuele Cortese has cracked a puzzle that affects millions: what dose of ADHD medication actually works best. Analyzing data from 113 clinical trials involving more than 25,000 people with the condition, researchers have mapped out the "sweet spot" for five commonly prescribed ADHD medications—the point where effectiveness peaks without tipping into unnecessary side effects.
This matters because ADHD, which affects about 5% of school-age children and 2% to 3% of adults, is treated primarily through medication, yet most clinical guidelines offer surprisingly little guidance on optimal dosing. Prescriptions have surged in recent years, but without clear landmarks, many patients end up on doses that are either too low to help or high enough to cause unwanted effects. The new study, published in The Lancet Psychiatry, uses an advanced method called dose-effects network meta-analysis to map how different doses of each medication affect both symptom control and side effects.
The findings reveal important patterns. Dr. Mikail Nourredine from the University of Lyon, the study's first author, emphasized that "clinicians should avoid using doses that are too low to be effective. If symptoms are not well controlled, the dosage may need to be increased." This addresses a real clinical gap: research shows a substantial proportion of children and adolescents receive low dosages without appropriate increases, despite evidence that timely and adequate adjustments lead to better treatment adherence.
Yet the study also discovered something equally important: there's no evidence that exceeding licensed maximum doses improves average effectiveness. In fact, higher doses tend to bring more side effects without added benefit. The dosage patterns differ between medications and age groups, underscoring that one-size-fits-all approaches miss the mark.
What makes this research particularly promising is what comes next: Cortese's team has developed a free online tool based on the findings to help both clinicians and patients navigate these decisions together. This reflects a crucial shift in how medication decisions should work. "It is not only a clinician's decision—patients and caregivers should be involved," Cortese said. The tool translates the research into something tangible: it shows what patients can expect from each dose, helping them understand why a particular dose was chosen.
That said, the researchers acknowledge an important caveat. Their results come from group averages, meaning some individuals with ADHD may benefit from doses outside the licensed range and tolerate them well. "We are continuing research to further personalize these recommendations based on individual patient characteristics," Cortese noted, suggesting the next frontier involves moving beyond population-level guidance toward tailored approaches.
For the millions taking ADHD medication, the message is straightforward but empowering: there are evidence-based dosage ranges that work better than others, neither too timid nor excessive. The research gives clinicians and patients a shared language for those crucial conversations about finding the right fit.